India Glycols

₹778 9.5 | 1.2%

WEBSITE BSE:500201 NSE : IND.GLYCOLS 10 May, 16:01

Market Cap ₹2409 Cr.

Stock P/E 14.1

P/B 1.2

Current Price ₹778

Book Value ₹ 646.9

Face Value 10

52W High ₹978.9

Dividend Yield 0.96%

52W Low ₹ 575.2

Edit Ratio

India Glycols Research see more...

Overview Inc. Year: 1983Industry: Chemicals

India Glycols Ltd is engaged in production of Industrial Chemicals such as green technology-based bulk, speciality and performance chemical compounds, and natural gums, industrial gases; Ethyl Alcohol (Potable), and nutraceuticals. It’s segments include Glycol Ethers, Glycol Ether Acetates, Power Alcohol (Bio Fuel), Industrial Gases, Ethylene Oxide Derivatives (EODs), Bio-based Glycols (MEG, DEG, TEG and Heavy Glycols),Natural Gum (Bio Polymers), Ethyl Alcohol (Potable Spirits) and Extra Neutral Alcohol (ENA)and Ennature Biopharma (Nutraceuticals). Its merchandise are Glycols (Bio-Based Specialties and Performance Chemicals), Ethyl Alcohol (Potable Spirits), Plant-primarily based APIs and Nutraceuticals, Natural Gums (Bio Polymers), and Derivatives and Industrial Gases.

India Glycols Share Price

New

Volume

Price

Price: NSE50 DMA200 DMAVolume

Quarterly Price

Quarterly Monthly

Show Value Show %

Peer Comparison

India Glycols Quarterly Results

#(Fig in Cr.)	Sep 2021	Dec 2021	Mar 2022	Jun 2022	Sep 2022	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023
Net Sales	1695	1760	1494	1868	1634	1524	1616	1894	1870	2119
Other Income	8	7	5	6	6	7	4	6	11	5
Total Income	1704	1767	1499	1874	1640	1531	1620	1899	1881	2123
Total Expenditure	1629	1706	1415	1805	1566	1455	1520	1794	1774	2017
Operating Profit	75	62	84	69	74	76	100	106	106	107
Interest	17	17	18	22	24	27	26	28	29	31
Depreciation	20	20	21	21	21	21	30	21	28	26
Exceptional Income / Expenses	0	0	-19	0	0	28	0	0	0	0
Profit Before Tax	38	25	27	25	28	56	44	58	49	49
Provision for Tax	10	7	-35	7	8	3	6	13	12	12
Profit After Tax	29	17	62	18	21	52	39	45	37	37
Adjustments	9	7	5	11	4	-22	2	6	1	5
Profit After Adjustments	37	24	67	29	25	31	40	51	38	42
Adjusted Earnings Per Share	12	7.8	21.7	9.4	8.1	9.9	13	16.5	12.3	13.4

India Glycols Profit & Loss

#(Fig in Cr.)	Mar 2013	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	TTM
Net Sales	3423	2977	2579	2324	2500	3034	3357	2735	2317	2868	2651	7499
Other Income	48	27	58	17	60	131	29	17	21	157	27	26
Total Income	3471	3004	2637	2341	2560	3165	3385	2752	2338	3025	2678	7523
Total Expenditure	3070	2775	2456	2146	2310	2813	2945	2462	2052	2745	2355	7105
Operating Profit	401	229	181	195	250	353	440	291	286	280	323	419
Interest	171	158	179	146	133	131	150	100	87	73	103	114
Depreciation	90	91	89	69	72	73	76	78	80	80	94	105
Exceptional Income / Expenses	0	-192	-58	-61	0	0	0	0	0	221	28	0
Profit Before Tax	140	-212	-144	-81	45	147	213	113	120	369	165	200
Provision for Tax	44	-50	-55	-24	10	51	81	38	11	39	24	43
Profit After Tax	96	-161	-89	-57	35	97	133	75	109	330	141	158
Adjustments	0	0	0	0	0	0	0	40	22	10	-16	14
Profit After Adjustments	96	-161	-89	-57	35	97	133	115	132	340	125	171
Adjusted Earnings Per Share	30.9	-52.1	-28.6	-18.3	11.3	31.2	42.8	37	42.5	109.8	40.4	55.2

Growth Rates

#	1 Year	3 Year	5 Year	10 Year
Sales CAGR	-8%	-1%	-3%	-3%
Operating Profit CAGR	15%	4%	-2%	-2%
PAT CAGR	-57%	23%	8%	4%

#	1 Year	3 Year	5 Year	10 Year
Share Price CAGR	36%	15%	26%	23%
ROE Average	8%	13%	12%	2%
ROCE Average	9%	12%	13%	10%

India Glycols Balance Sheet

#(Fig in Cr.)	Mar 2013	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023
Shareholder's Funds	536	372	297	718	752	845	963	1034	1169	1792	1901
Minority's Interest	0	0	0	0	0	0	0	0	0	-19	0
Borrowings	717	709	401	195	65	172	396	407	508	540	551
Other Non-Current Liabilities	167	119	58	870	773	739	701	661	675	570	541
Total Current Liabilities	1770	2083	2399	1836	1902	1665	1725	1984	1733	1749	1865
Total Liabilities	3191	3284	3155	3620	3492	3421	3784	4086	4119	4631	4858
Fixed Assets	1216	1309	1146	2029	2110	2155	2165	2220	2185	2310	2709
Other Non-Current Assets	274	203	227	311	248	185	232	269	223	712	502
Total Current Assets	1700	1772	1782	1277	1132	1079	1385	1595	1328	1607	1646
Total Assets	3191	3284	3155	3620	3492	3421	3784	4086	4119	4631	4858

India Glycols Cash Flow

#(Fig in Cr.)	Mar 2013	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023
Opening Cash & Cash Equivalents	52	60	22	22	6	5	5	27	4	3	7
Cash Flow from Operating Activities	817	-234	-171	1231	302	502	147	343	137	116	326
Cash Flow from Investing Activities	-227	110	175	-78	-40	-103	-128	-151	-148	76	-330
Cash Flow from Financing Activities	-582	87	-4	-1168	-263	-399	3	-216	11	-189	-1
Net Cash Inflow / Outflow	8	-37	-0	-15	-1	-0	22	-23	-0	4	-5
Closing Cash & Cash Equivalent	60	22	22	6	5	5	27	4	3	7	2

India Glycols Ratios

#	Mar 2013	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023
Earnings Per Share (Rs)	30.85	-52.12	-28.63	-18.35	11.32	31.18	42.83	37.03	42.51	109.77	40.4
CEPS(Rs)	59.98	-22.85	0.05	4.09	34.59	54.78	67.46	49.22	61.15	132.38	75.9
DPS(Rs)	6	1	0	0	1	4	6	6	6	7.5	7.5
Book NAV/Share(Rs)	173.06	120.3	95.94	230.83	242.15	272.2	310.14	333.29	376.92	578.4	613.91
Core EBITDA Margin(%)	8.93	5.69	3.93	5.43	5.26	5.33	8.04	5.25	4.88	1.87	4.45
EBIT Margin(%)	7.87	-1.5	1.1	1.96	4.93	6.69	7.09	4.08	3.81	6.7	4.04
Pre Tax Margin(%)	3.53	-5.96	-4.57	-2.48	1.25	3.54	4.16	2.16	2.22	5.59	2.48
PAT Margin (%)	2.42	-4.55	-2.81	-1.73	0.97	2.32	2.59	1.43	2.01	4.99	2.12
Cash Profit Margin (%)	4.7	-1.99	0	0.39	2.97	4.08	4.08	2.92	3.49	6.21	3.54
ROA(%)	3.01	-4.98	-2.75	-1.68	0.99	2.79	3.68	1.9	2.66	7.53	2.97
ROE(%)	20.12	-35.53	-26.48	-11.26	4.79	12.12	14.71	7.51	9.93	22.29	7.64
ROCE(%)	12.74	-2.25	1.39	2.86	9.39	15.8	19.95	10.72	9.62	17.28	9.21
Receivable days	27.47	37.88	50.84	44.6	38.12	31.75	23.38	31.16	31.29	21.02	22.78
Inventory Days	58.67	59.54	62.19	55.85	52.27	42.35	39.05	46.5	43.44	36.02	39.76
Payable days	65.02	93.81	82.18	100.8	131.47	132.59	146.21	157.26	177.51	130.1	193.25
PER(x)	4.13	0	0	0	14.14	14.51	6.53	5.75	9.81	9.22	15.19
Price/Book(x)	0.74	0.79	0.85	0.37	0.66	1.66	0.9	0.64	1.11	1.75	1
Dividend Yield(%)	4.7	1.06	0	0	0.62	0.88	2.15	2.82	1.44	0.74	1.22
EV/Net Sales(x)	0.59	0.73	0.91	0.63	0.62	0.72	0.52	0.57	1	1.42	1.09
EV/Core EBITDA(x)	5.06	9.52	12.97	7.5	6.24	6.17	3.98	5.32	8.09	14.52	8.93
Net Sales Growth(%)	24.1	-13.03	-13.34	-9.9	7.54	21.39	10.62	-18.51	-15.3	23.79	-7.58
EBIT Growth(%)	14.67	-117.09	165.33	85.48	176.68	56.21	30.42	-41.34	-2.75	113.72	-39.36
PAT Growth(%)	41.72	-268.91	45.06	35.92	161.69	175.45	37.39	-43.56	45.89	201.81	-57.21
EPS Growth(%)	27.63	-268.91	45.06	35.92	161.69	175.44	37.39	-13.54	14.78	158.23	-63.19
Debt/Equity(x)	3.3	5.51	7.62	1.73	1.46	0.99	1.04	0.95	0.96	0.58	0.58
Current Ratio(x)	0.96	0.85	0.74	0.7	0.59	0.65	0.8	0.8	0.77	0.92	0.88
Quick Ratio(x)	0.64	0.57	0.54	0.41	0.32	0.38	0.43	0.46	0.41	0.52	0.48
Interest Cover(x)	1.81	-0.34	0.19	0.44	1.34	2.12	2.42	2.13	2.39	6.03	2.6
Total Debt/Mcap(x)	4.48	7	9	4.7	2.21	0.6	1.16	1.49	0.87	0.33	0.58

India Glycols Shareholding Pattern

#	Dec 2021	Mar 2022	Jun 2022	Sep 2022	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024
Promoter	61.01	61.01	61.01	61.01	61.01	61.01	61.01	61.01	61.01	61.01
FII	2.19	2.18	1.31	1.31	1.22	1.17	1.16	1.29	1.57	1.8
DII	4.39	4.62	5.2	3.75	3.76	4.17	1.97	0.06	0.11	0.08
Public	32.41	32.19	32.47	33.93	34.01	33.64	35.86	37.63	37.3	37.11
Others	0	0	0	0	0	0	0	0	0	0
Total	100	100	100	100	100	100	100	100	100	100

#	Dec 2021	Mar 2022	Jun 2022	Sep 2022	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024
Promoter	1.89	1.89	1.89	1.89	1.89	1.89	1.89	1.89	1.89	1.89
FII	0.07	0.07	0.04	0.04	0.04	0.04	0.04	0.04	0.05	0.06
DII	0.14	0.14	0.16	0.12	0.12	0.13	0.06	0	0	0
Public	1	1	1.01	1.05	1.05	1.04	1.11	1.17	1.15	1.15
Others	0	0	0	0	0	0	0	0	0	0
Total	3.1	3.1	3.1	3.1	3.1	3.1	3.1	3.1	3.1	3.1

Pros

Cons

Company has a low return on equity of 13% over the last 3 years.
Debtor days have increased from 130.1 to 193.25days.
The company has delivered a poor profit growth of 7% over past five years.

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.